--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-23-222968" form_type: "8-K" ticker: "CLDI" cik: "0001855485" company_name: "Calidi Biotherapeutics, Inc." filed_at: "2023-08-29T23:59:59+00:00" generated_at: "2026-06-11T02:32:43.141691+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.65 calibrated_materiality_score: 0.65 confidence: "high" source: SEC EDGAR --- # FLAG shareholders approve Calidi merger; enters forward purchase & non-redemption agreements ## Summary - Stockholders voted 7,039,109 for and 242,945 against the business combination with Calidi Biotherapeutics. - Entered Forward Purchase Agreement with Meteora entities to purchase up to 340,000 shares of Class A common stock. - Non-Redemption Agreement reverses 129,524 shares; New Calidi to pay ~$680,000 in cash upon closing. - Series B financing from Jackson Investment Group and Calidi Cure totals $25 million; Meteora commits additional ~$1.02 million. - Trust account estimated per-share redemption price of approximately $10.49 as of August 30, 2023. ## SEC filing metadata - accession: 0001193125-23-222968 - form_type: 8-K - ticker: CLDI - cik: 0001855485 - company_name: Calidi Biotherapeutics, Inc. - filed_at: 2023-08-29T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.65 - calibrated_materiality_score: 0.65 - confidence: high - sec_items: 1.01, 5.07, 8.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000119312523222968/0001193125-23-222968-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000119312523222968/d526016d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-23-222968 - JSON: https://secwatch.observer/filing/0001193125-23-222968.json - Plain text: https://secwatch.observer/filing/0001193125-23-222968.txt ## Key facts - Material Agreements Calidi Biotherapeutics, Inc. entered into Forward Purchase Agreement with Meteora Strategic Capital, LLC, Meteora Capital Partners, LP and Meteora Select Trading Opportunities Master, LP (collectively, Seller) valued at aggregate amount equal to up to 340,000 shares of Class A Common Stock (effective 2023-08-28). - Action: entry - Agreement: equity purchase - Counterparty: Meteora Strategic Capital, LLC, Meteora Capital Partners, LP and Meteora Select Trading Opportunities Master, LP (collectively, Seller) - Value: aggregate amount equal to up to 340,000 shares of Class A Common Stock - Effective: 2023-08-28 source text: On August 28, 2023, FLAG and Calidi entered into a forward purchase agreement (the “Forward Purchase Agreement”) with each of (i) Meteora Strategic Capital, LLC (“MSC”), Meteora Capital Partners, LP (“MCP”) and Meteora Select Trading Opportunities Master, LP (“MSTO”) (with MSC, MCP, and MSTO collectively as “Seller") for an OTC Equity Prepaid Forward Transaction. evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000119312523222968/0001193125-23-222968-index.htm - Shareholder Votes Calidi Biotherapeutics, Inc. shareholders approved Approve that stockholder action may not be taken by written consent at the 2023-08-28 meeting. - Outcome: passed - Meeting: 2023-08-28 source text: For Against Abstain 6,970,882 311,172 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000119312523222968/0001193125-23-222968-index.htm - Shareholder Votes Calidi Biotherapeutics, Inc. shareholders approved Approve and adopt the Second Amended and Restated Certificate of Incorporation at the 2023-08-28 meeting. - Proposal: charter amendment - Outcome: passed - Meeting: 2023-08-28 source text: For Against Abstain 7,039,109 242,945 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000119312523222968/0001193125-23-222968-index.htm - Shareholder Votes Calidi Biotherapeutics, Inc. shareholders approved Approve the Employee Stock Purchase Plan at the 2023-08-28 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2023-08-28 source text: For Against Abstain 6,970,982 311,072 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000119312523222968/0001193125-23-222968-index.htm - Shareholder Votes Calidi Biotherapeutics, Inc. shareholders approved Approve the business combination at the 2023-08-28 meeting. - Proposal: merger approval - Outcome: passed - Meeting: 2023-08-28 source text: For Against Abstain 7,039,109 242,945 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000119312523222968/0001193125-23-222968-index.htm - Shareholder Votes Calidi Biotherapeutics, Inc. shareholders approved Approve the change in authorized capital stock at the 2023-08-28 meeting. - Outcome: passed - Meeting: 2023-08-28 source text: For Against Abstain 7,039,109 242,945 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000119312523222968/0001193125-23-222968-index.htm - Shareholder Votes Calidi Biotherapeutics, Inc. shareholders approved Approve that directors may be removed only for cause by 66 2/3% vote at the 2023-08-28 meeting. - Outcome: passed - Meeting: 2023-08-28 source text: For Against Abstain 6,970,882 311,172 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000119312523222968/0001193125-23-222968-index.htm - Shareholder Votes Calidi Biotherapeutics, Inc. shareholders approved Approve the 2023 Stock Incentive Plan at the 2023-08-28 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2023-08-28 source text: For Against Abstain 6,943,786 338,268 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000119312523222968/0001193125-23-222968-index.htm - Shareholder Votes Calidi Biotherapeutics, Inc. shareholders approved Elect seven directors to serve on the New Calidi board at the 2023-08-28 meeting. - Proposal: director election - Outcome: passed - Meeting: 2023-08-28 source text: Director For Against Abstain Allan Camaisa 7,241,490 0 40,564 evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000119312523222968/0001193125-23-222968-index.htm - Shareholder Votes Calidi Biotherapeutics, Inc. shareholders approved Approve provisions requiring 66 2/3% vote for bylaw amendments and certain charter provisions at the 2023-08-28 meeting. - Proposal: charter amendment - Outcome: passed - Meeting: 2023-08-28 source text: For Against Abstain 6,970,982 311,072 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000119312523222968/0001193125-23-222968-index.htm - Shareholder Votes Calidi Biotherapeutics, Inc. shareholders approved Approve issuance of more than 20% of common stock in connection with business combination at the 2023-08-28 meeting. - Proposal: merger approval - Outcome: passed - Meeting: 2023-08-28 source text: For Against Abstain 6,970,982 311,072 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000119312523222968/0001193125-23-222968-index.htm - Shareholder Votes Calidi Biotherapeutics, Inc. shareholders approved Adjourn the special meeting if necessary at the 2023-08-28 meeting. - Outcome: passed - Meeting: 2023-08-28 source text: For Against Abstain 6,970,982 311,072 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000119312523222968/0001193125-23-222968-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.